
Orgasm Inc: The Story of OneTaste
2022

Representation Score
Good
2009
Not RatedDirector
Elizabeth Canner
Runtime
73 minutes
Average Rating
No ratings yetNew Showbiz Analysis
Orgasm Inc. critically examines the pharmaceutical industry's efforts to commodify female pleasure. By focusing on the race to develop a 'female Viagra,' the film highlights the systemic forces that manage and monetize intimacy. The documentary successfully deconstructs how corporate capitalism intersects with human desire, moving beyond a simple scientific report. While the film excels in critiquing gendered issues, it appears limited in its racial and ethnic breadth, with a focus remaining largely within the high-level biotech corporate structures of the time.
Category Breakdown
The film delves into the complexities of sexual desire and arousal, offering a platform to discuss sexual identity beyond traditional, rigid frameworks.
The documentary challenges traditional hierarchies by emphasizing female biological ability to act and pleasure. It questions historical medical paradigms that favored male performance over female sexual health.
The narrative centers around corporate and clinical pharmaceutical environments, with limited evidence of a diverse cast driving the central narrative arcs within these professional settings.
The film offers a sophisticated critique of Western capitalist institutions, examining the tension between profit motives and the ethics of monetizing human intimacy.
The film does not focus on specific themes of disability, so no meaningful assessment can be made regarding this category.
Present on Screen
Limited or Absent
Official Synopsis
Extraordinary behind-the-scenes access reveals a drug company's fevered race to develop the first FDA-approved Viagra for women - and offers a humorous but sobering look inside the cash-fueled pharmaceutical industry.

2022

2012

2020

2010

2008

2011

2021

2019
No reviews yet. Be the first to share your thoughts on this movie!
Use the rating form above to leave a star rating and optional review.